Scopus BioPharma Inc. financial data

Symbol
SCPS on OTC
Industry
Pharmaceutical Preparations
Location
420 Lexington Avenue, Suite 300, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2023 - Aug 11, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity 122 %
Return On Assets -1.2K % -248%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.1M shares +99.5%
Common Stock, Shares, Outstanding 39.6M shares +87.7%
Common Stock, Value, Issued 39.8K USD +88.6%
Weighted Average Number of Shares Outstanding, Basic 39.7M shares +88.4%
Weighted Average Number of Shares Outstanding, Diluted 39.7M shares +88.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 5.27M USD +327%
General and Administrative Expense 4.08M USD -74.6%
Net Income (Loss) Attributable to Parent -8.7M USD +45.3%
Earnings Per Share, Basic -0.32 USD/shares +57.3%
Earnings Per Share, Diluted -0.32 USD/shares +57.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 362K USD -68.7%
Assets, Current 496K USD -70.3%
Property, Plant and Equipment, Net 1.7K USD -39.5%
Assets 498K USD -70.3%
Liabilities, Current 11M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 30.2K USD
Retained Earnings (Accumulated Deficit) -58.1M USD -17.6%
Stockholders' Equity Attributable to Parent -9.45M USD -156%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -10.5M USD
Liabilities and Equity 498K USD -70.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -760K USD +80.9%
Net Cash Provided by (Used in) Financing Activities 2.02M USD
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 39.8M shares +88.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.28M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 362K USD -68.7%
Depreciation 334 USD -42.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -8.65M USD +45.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 48.6M USD +6.31%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 318K USD -35%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%